Blue Cross' Antitrust Suit Belongs In NJ, Janssen Says
Blue Cross Blue Shield should have to pursue its claims that Janssen Biotech used "sham" patent infringement litigation to delay generic competition to prostate cancer drug Zytiga in front of the...To view the full article, register now.
Already a subscriber? Click here to view full article